Tesamorelin boosts a key growth hormone-related protein in HIV patients without affecting their blood sugar levels.

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension

Randomized Controlled Trial

Human

2010 Mar

The study found that tesamorelin raised a growth-related hormone (IGF-I) in HIV patients without affecting their blood sugar, which is exactly what the claim says.

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Source Study

Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension

Score: 81

DOI: 10.1097/QAI.0b013e3181cbdaff

Similar Assertions

The injection makes the body produce more of a natural growth-related hormone called IGF-1, which helps explain how it reduces belly fat.

86%

The drug makes the body produce more IGF-1 — a hormone linked to growth and metabolism — which is exactly what you’d expect from a drug that stimulates growth hormone.

86%

For people with HIV taking tesamorelin, changes in their growth hormone levels didn't match changes in their trunk muscle thickness or size.

86%

People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had higher levels of a growth-related hormone called IGF-1. This finding is from the abstract summary - full study details were not available

85%

Changes in a growth hormone-related factor didn't match changes in muscle density or size in people with HIV and belly fat taking tesamorelin.

81%